Pfizer completes acquisition of ReViral
04/06/24, 6:34 AM
Location
Pfizer has announced the successful completion of its acquisition of ReViral, a clinical-stage biopharmaceutical company focused on antiviral therapeutics targeting respiratory syncytial virus (RSV). The acquisition brings ReViral’s portfolio of promising therapeutic candidates, including sisunatovir, into Pfizer’s anti-infective pipeline, further demonstrating Pfizer’s commitment to advancing pioneering science and delivering breakthroughs to patients suffering from serious infectious diseases.
Company Info
Location
New York, New York, United States
Company info
Breakthroughs That Change Patients' Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.To learn more, visit www.pfizer.com.
For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
Beware of scams from individuals, organizations and Internet sites claiming to represent Pfizer in recruitment activities. A formal Pfizer recruitment process is required for all authorized positions posted by Pfizer prior to issuing an offer of employment. This Pfizer process includes an interview and never requires payment or fees from job applicants. If you receive a suspicious email message or phone call about recruiting on behalf of Pfizer, do not provide any personal information or pay any fees. Interested candidates should apply to current openings through this Pfizer website. Pfizer accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.